Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

92 results about "Cellular activity" patented technology

Method for distinguishing cell activity behaviors in culture medium under assistance of computer

The invention provides a method for distinguishing cell activity behaviors in a culture medium under the assistance of a computer, and relates to the technical field of cell image processing, and the method comprises the following steps: obtaining a target microscopic image of a target cell at the current moment, extracting the static characteristics of the target cell in the target microscopic image, and if the recognition confidence is lower than a first threshold value, determining that the target cell is a cell activity behavior; if yes, calling a historical image sequence of an area where the target cell is located; at least N candidate images are obtained through screening in the historical image sequence, time sequence dynamic characteristics of the target cells are obtained based on the candidate images, and the time sequence dynamic characteristics comprise the motion trail, the motion speed, the morphological change related to the activity behavior and the periodic change condition presented by the target cells within a certain time period; and combining the time sequence dynamic characteristics with the static characteristics, and carrying out activity behavior matching to obtain activity behaviors of the target cells. According to the method, the robustness and the accuracy of cell behavior recognition in a complex culture environment are remarkably improved through static-dynamic feature fusion.
Owner:YANJIN (TIANJIN) TECHNOLOGY CO LTD

Receptors providing targeted costimulation for adoptive cell therapy

The present invention relates to a chimeric costimulatory antigen receptor (CoStAR) useful in adoptive cell therapy (ACT), and cells comprising the CoStAR. The CoStAR can act as a modulator of cellular activity enhancing responses to defined antigens. The present invention also provides CoStAR proteins, nucleic acids encoding the CoStAR and therapeutic uses thereof.
Owner:INSTIL BIO UK LTD +1

Antibody drug conjugate as well as preparation method and application thereof

The invention relates to an antibody drug conjugate which is shown in a formula (I) and contains two or more bioactive molecules with different action mechanisms, a preparation method of the antibody drug conjugate, and application of the antibody drug conjugate in prevention and / or treatment of diseases related to abnormal cell activity, including but not limited to prevention and / or treatment of tumor diseases. # imgabs0 #
Owner:MEDILINK THERAPEUTICS (SUZHOU) CO LTD

Composite hydrogel with biological activity, scaffold and application of composite hydrogel

InactiveCN119119709A
The invention relates to a composite hydrogel with biological activity, a scaffold and application thereof. The composite hydrogel is prepared from the following components: 5 to 25 weight percent of polyethylene glycol diacrylate, 2 to 20 weight percent of collagen, 1 to 6 weight percent of hyaluronic acid and cell growth factors. The composite hydrogel has biological activity and viscosity, and supports cell activities such as cell proliferation, migration and differentiation; the hardness in a material system can be adjusted to be matched with the actual hardness of the microenvironment of each tissue organ, so that the functions of further promoting cell growth and differentiation are achieved. The composite hydrogel with biological activity and the scaffold prepared from the composite hydrogel can be applied to various basic researches including interaction between cells and tissue microenvironments, intracellular molecular biological signals, organ reactions, drug screening models and the like.
Owner:BEOGENE BIOTECH GUANGZHOU

Bioactive substance conjugate and preparation method and use thereof

The present disclosure relates to bioactive conjugates and preparation methods and uses thereof, and specifically discloses a ligand-drug conjugate represented by formula XV, a preparation method thereof, and its use in preventing and / or treating diseases associated with abnormal cell activity, including but not limited to preventing and / or treating tumor diseases. #imgabs0#
Owner:MEDILINK THERAPEUTICS (SUZHOU) CO LTD

Antibody-auristatins drug conjugate and use thereof

An antibody-drug conjugate as shown in formula I, a preparation method therefor, and a use thereof in prevention and / or treatment of diseases related to abnormal cell activity, including but not limited to a use in prevention and / or treatment of tumor diseases.
Owner:MEDILINK THERAPEUTICS (SUZHOU) CO LTD

Cyclic dinucleotide prodrug molecule and preparation method and application thereof

The present invention relates to the field of medicines, and discloses a cyclic dinucleotide prodrug molecule and a preparation method and application thereof. The cyclic dinucleotide prodrug molecule has a structure as shown in Formula I, Formula II or Formula III, can autonomously cross the cell membrane, release the cyclic dinucleotide, and has high cell activity.
Owner:SHENZHEN YING BIOPHARMACEUTICAL CO LTD

Nuclear localization signals, compositions formed therefrom, and methods of use thereof for delivery of cargo to the nucleus

Amino acid sequences capable of enhancing nuclear translocation are provided. Also referred to a nuclear localization signals (NLS) the sequences can be linked to or grafted into antibodies or fragments or fusion proteins thereof to enhance nuclear translocation of the antibody. Compositions and antibodies including an NLS conjugated or otherwise linked directly or indirectly to an active agent cargo are also provided. Exemplary cargo includes proteins, peptides, carbohydrates, polysaccharides, nucleic acid molecules, inorganic molecules, organic molecules, and diagnostic agents. Pharmaceutical compositions further including a pharmaceutically acceptable carrier are also provided. Methods of delivering the composition or antibody alone or with a cargo linked thereto to the nucleus of cell, methods of selecting or screening for compositions having a desired cellular activity, and methods of treating diseases and disorders are also provided.
Owner:YALE UNIVERSITY

Polymeric particles for proximity-based cellular DNA-encoded library screening and methods of use

Provided herein are compositions comprising a particle comprising a library encoded bead (e.g., DEL bead) coated in a polymeric matrix forming a core-shell particle, wherein the core-shell particle is further inside a 3D tissue culture. Also provided herein are methods of making such particles, and methods of using such particles for drug discovery such as identification of bioactive compounds via high-throughput cellular activity-based phenotypic screens of DNA-encoded chemical library beads.
Owner:GENENTECH INC +1

Differential low-noise integrated biosensor array for cell culture detection and preparation method of differential low-noise integrated biosensor array

The invention discloses a differential low-noise integrated biosensor array for cell culture detection and a preparation method thereof, and the differential low-noise integrated biosensor array integrates an ISHFET device, an REHFET device and an EXHFET device, so that extracellular action potential signals and local field potential signals can be detected during in-vitro cell culture; therefore, interference of factors such as tissue trauma and immune response on cell activity signal detection is avoided, and good reliability is realized; the ISHFET device and the REHFET device can form a differential sensing unit, so that the effect of reducing the detection error is realized; the EXHFET device not only can detect extracellular action potential signals, but also can independently detect local field potential signals, so that more diversified cell activity signals can be detected, and more data support is provided for in-vitro cell culture research. The method is widely applied to the technical field of semiconductors.
Owner:SUN YAT SEN UNIV

Chlamydomonas reinhardtii strain with high exosome yield

The invention relates to the technical field of microalgae biology, in particular to a chlamydomonas reinhardtii strain with high yield of exosomes, which is named as Chlamydomonas reinhardtii YYAW026 and preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC NO.46629, the preservation date is November 10, 2025, and the preservation address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing. Compared with an original strain, the chlamydomonas reinhardtii cell provided by the invention cannot form a complete cell wall structure, so that the exosome can be quickly secreted into a culture solution; although the cell structure of the strain is incomplete, the strain can still perform normal cell activity, the growth curve is basically consistent with that of a wild type, the yield of the exosome of the strain is greater than that of the wild type when the strain reaches a plateau phase, and the particle size distribution width of the exosome is more concentrated. The chlamydomonas reinhardtii disclosed by the invention has a relatively good application prospect in the basic research fields of cosmetics, medical beauty industry and algae source exosomes.
Owner:SHENZHEN PROTOGA BIOTECH CO LTD +2

Pharmaceutical combination of PRMT5 inhibitors

This disclosure relates to pharmaceutical combinations for treating and / or preventing cancer and methods and uses thereof. More particularly, provided are pharmaceutical combination comprising a PRMT5 Inhibitor and a cellular activity modulator selected from an EGFR inhibitor, a KRAS inhibitor, a KRAS-G12C inhibitor, a MEK inhibitor, a Bcl-2 inhibitor, a SOS1 inhibitor, a PARP inhibitor, a RAF inhibitor, a ERK inhibitor, a CDK4 / 6 inhibitor, a MALT1 inhibitor, a BTK inhibitor, MAT2A inhibitor, a PI3K inhibitor, a AKT inhibitor, a FGFR inhibitor, a Type I PRMT inhibitor, a STING agonist, or an immune checkpoint inhibitor / modulator.
Owner:LUPIN LTD

Nucleic acid encoding ATP7b, adeno-associated virus vector and use thereof in preparing drug for preventing and treating wilson's disease

PCT designated stage expiredWO2025002226A1Nervous disorderPeptide/protein ingredientsTissue specificAtp7b gene
The present invention relates to a nucleic acid encoding ATP7B, an adeno-associated virus vector, and a use thereof in preparing a drug for preventing and treating Wilson's disease. Provided is an ATP7B GOI vector that can be packaged into an adeno-associated virus having cellular activity, relatively high yield and good integrity, which can be used in AAV gene therapy for WD. By means of using an engineered tissue-specific promoter and a truncated natural ATP7B gene having a unique sequence, the sequence length is suitable for packaging into an active adeno-associated virus particle, potential side effects caused by gene expression in tissues other than the liver are minimized, and it is expected to have better in vivo safety.
Owner:MABWELL (SHANGHAI) BIOSCIENCE CO LTD

Bioactive matter conjugate as well as preparation method and application thereof

The invention relates to a bioactive substance conjugate and a preparation method and application thereof, in particular to a novel bioactive molecule conjugate obtained by improving the coupling mode of a drug in ADC or SMDC and a targeting part, a preparation method of the novel bioactive molecule conjugate and application of the novel bioactive molecule conjugate to preparation of drugs for treating cell activity abnormity related diseases.
Owner:SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD

Antibody drug conjugate as well as preparation method and application thereof

The invention relates to an antibody drug conjugate of a cardiac glycoside and / or cardiac aglycone compound as shown in a formula (I), a preparation method of the antibody drug conjugate and application of the antibody drug conjugate in prevention and / or treatment of diseases related to abnormal cell activity, including but not limited to prevention and / or treatment of tumor diseases. # imgabs0 #
Owner:MEDILINK THERAPEUTICS (SUZHOU) CO LTD

Method and device for pain modulation by optical activation of neurons and other cells

This invention, in one aspect, relates generally to methods for optically modulating pain in animals and human. The invention provides method for the use of opsin for modulating pain, wherein optical stimulation of specific neurons and / or other cells in targeted regions of the nervous system sensitized by opsin, using genetic technologies, leads to significant reduction of pain perception to noxious stimuli. Further, the invention provides a method for inhibition of pain without use of exogenous opsin, wherein visual stimulation of eye (having endogenous opsin) is carried out. The invention also includes device(s) for controlled modulation neural and / or cellular activities in brain, eye and peripheral nervous system in order to treat different forms of chronic pain.
Owner:OPSIN BIOTHERAPEUTICS INC

B-catenin / B-cell Lymphoma 9 protein-protein interaction inhibiting peptidomimetics

Disclosed herein is a series of helical sulfono-γ-AApeptides that mimic the binding mode of the α-helical HD2 domain of B-Cell Lymphoma 9 (BCL9). As disclosed herein, sulfono-γ-AApeptides can structurally and functionally mimic the α-helical domain of BCL9, and selectively disrupt β-catenin / BCL9 PPIs with even higher potency. More intriguingly, these sulfono-γ-AApeptides can enter cancer cells, bind with β-catenin and disrupt β-catenin / BCL PPI, and exhibit excellent cellular activity, which is much more potent than the BCL9 peptide. Furthermore, enzymatic stability studies demonstrated the remarkable stability of the helical sulfono-γ-AApeptides, with no degradation in the presence of pronase for 24 h, augmenting their biological potential.
Owner:UNIV OF SOUTH FLORIDA +1

Single vision spectacle lenses can be converted into myopia management spectacle lenses with non-refractive opaque characteristic optical films

The present disclosure relates to means for treating axial length disorders, such as myopia, and includes apparatus and methods for prescribing, selecting, supplying, and fitting permanent or non-permanent optical films for use with standard single-vision eyeglasses, wherein the apparatus and methods are configured with non-refractive opaque features, wherein the non-refractive opaque features promote an increase in retinal ganglion cell activity throughout the wearer's retina, which can be used as an optical signal to slow, improve, control, inhibit, or reduce the rate of myopia progression in the wearer.
Owner:NTHALMIC HLDG PTY LTD

Application of rice ospdra3 gene in improving rice resistance to pests

ActiveCN121950832BBiotechnologyWild type
This invention provides rice OsPDRA3 Application of genes in improving insect resistance in rice. This invention clones genes from the rice genome. OsPDRA3 Gene (LOC_Os01g42380), analyzed using the SMART program, predicts that this protein possesses multiple transmembrane domains and ATPase domains (AAA+) associated with various cellular activities. Further investigation is needed. OsPDRA3 The effect on tolerance of rice brown planthopper was investigated by comparing wild-type and overexpression. OsPDRA3 The tolerance of transgenic plants to brown planthoppers was assessed, and the results showed that overexpression of [the planthopper species]... OsPDRA3 Compared to wild-type rice lines (0% survival rate), the survival rate of rice lines treated with brown planthoppers was significantly improved, reaching 75%–100%. This indicates that… OsPDRA3 Genes can significantly improve the insect resistance of rice and can be widely used in the fields of plant genetic engineering and plant disease resistance, with huge economic value and application prospects.
Owner:SUN YAT SEN UNIV

A quinazoline derivative and uses thereof

The present application relates to a quinazoline derivative of general formula (I) or stereoisomer, pharmaceutically acceptable salt, solvate, or tautomer, which can selectively inhibit CDK9 and / or TNIK, and has good enzymatic and cellular activity.
Owner:SCINNOHUB PHARM CO LTD

Bioactive matter conjugate as well as preparation method and application thereof

The invention relates to a bioactive substance conjugate as well as a preparation method and application thereof, and particularly discloses a ligand drug conjugate as shown in a formula XV, a preparation method thereof and application of the ligand drug conjugate in prevention and / or treatment of diseases related to abnormal cell activity, including but not limited to prevention and / or treatment of tumor diseases. # imgabs0 #
Owner:MEDILINK THERAPEUTICS (SUZHOU) CO LTD

Method of treatment via intra-articular application of potassium

Resolution of a pathological condition is promoted via the application, e.g., via injection, of a potassium osmolyte such as hyperosmolar potassium gluconate, potassium aspartate, another potassium-based salt, or combinations thereof to the condition site. The application of the potassium osmolyte increases the extracellular concentration of potassium ions, reducing the membrane potential of the cells at the condition site and including immune cell quiescence. As a result, the inflammatory response in the patient to the pathological condition is reduced or eliminated. Reducing the inflammatory response is useful in treatment of myriad conditions including arthritis, auto-immune conditions, inflammatory disorders, neurodegenerative disorders, neurodevelopmental disorders, tissue breakdown, etc.
Owner:RENESSELAER POLYTECHNIC INST

Techniques for cell active time extension

PCT designated stage expiredWO2025049083A1Connection managementTelecommunicationsActive time
Methods, systems, and devices for wireless communications are described. A user equipment (UE) may receive control signaling that indicates a cell discontinuous reception (DRX) cycle for a cell communicating with the UE. In some examples, the cell DRX cycle may alternate between an active duration during which the cell may monitor for communications and an inactive duration during which the cell may refrain from monitoring for communications. In some examples, the UE may transmit a request to extend the active duration of the cell DRX cycle during one or more cycles of the cell DRX cycle based on a performance parameter associated with an uplink transmission satisfying a threshold. As such, the UE may transmit the uplink transmission during the active duration of a cycle that is extended based on transmitting the request.
Owner:QUALCOMM INC

Techniques for cell active time extension

Methods, systems, and devices for wireless communications are described. A user equipment (UE) may receive control signaling that indicates a cell discontinuous reception (DRX) cycle for a cell communicating with the UE. In some examples, the cell DRX cycle may alternate between an active duration during which the cell may monitor for communications and an inactive duration during which the cell may refrain from monitoring for communications. In some examples, the UE may transmit a request to extend the active duration of the cell DRX cycle during one or more cycles of the cell DRX cycle based on a performance parameter associated with an uplink transmission satisfying a threshold. As such, the UE may transmit the uplink transmission during the active duration of a cycle that is extended based on transmitting the request.
Owner:QUALCOMM INC

Systems and methods for measuring changes in cellular activity in live tissue

Provided herein are systems and methods for measuring cellular activity within a biological sample comprising living cells over an extended time period. In particular, provided herein are techniques for measuring changes in cellular activity within a tissue sample comprising living cells (e.g., a tissue section comprising living cells) during and / or after exposure to a first stimulus (e.g., a control stimulus) at a first time point and during and / or after exposure to a second stimulus (e.g., a non-control stimulus) (e.g., a pharmaceutical stimulus) at a second time point after the first time point.
Owner:ELEPHAS BIOSCIENCES CORP

1,2-dicarboxamide compounds as kinase inhibitors

The present invention relates to 1,2-dicarboxamide compounds of Formula (I); pharmaceutically acceptable salts, pharmaceutically acceptable stereoisomers, N-oxides or combination thereof, wherein 'X', 'Y', 'Z', ring A, ring B, R1, R2, R3, R4, R5, R6, 'm' and 'n' are as defined herein. The present invention also relates to 1,2-dicarboxamide compounds that modulate cellular activities like proliferation, differentiation, adhesion, migration and apoptosis by modulating protein kinase enzymatic activity. In particular the invention relates to compounds which inhibit, regulate, and / or modulate tyrosine kinases such as FLT1 (VEGFR1), FLT4 (VEGFR3), KDR (VEGFR2), MET (C-Met), MERTK (c-Mer), RET, AXL, TEK (TIE 2) and EGFR. The present disclosure relates to 1,2-dicarboxamide compounds for use in modulating kinase enzymatic activity and accordingly modulating kinase-dependent associated diseases and conditions such as cancers like Thyroid carcinoma, Ovarian carcinoma, Pancreatic carcinoma, Prostatic carcinoma, Renal cell carcinoma, Hepatocellular carcinoma, Breast carcinoma, Colorectal carcinoma, Oral squamous cell carcinoma, Colorectal, Lung adenocarcinoma or Endometrial cancer.
Owner:HETERO LABS LTD

Non-invasive magneto-acoustic apparatus for health tissue healing, regeneration and cancer regression

The present invention relates to a non-invasive magneto-acoustic apparatus for healthy tissue healing and cancer regression comprising at least one pulsed ultrasound unit (LIPUS), at least one permanent magnet, at least one module housing, at least one permanent magnets, at least one control system for controlling pulsed ultrasound unit to energize the unit with desired pulse duration, intensity and active / ON time. The invention is to synchronously use the low intensity pulsed ultrasound (LIPUS) and static magnetic field (SMF) to selectively activate cellular activities specific to cartilage, bone, skin leading to accelerated tissue healing, regeneration. The invention apparatus is to inhibit cancer cellular activities specific to cancers of breast, skin, bone leading to enhanced cancer regression, while leaving the healthy cells unaffected using magneto-acoustic apparatus appropriately. The apparatus exhibit no toxicity to healthy cells and can reduce overall treatment time and costs due to accelerated tissue repair and tumor regression.
Owner:COUNCIL OF SCI & IND RES

Bioactive matter conjugate as well as preparation method and application thereof

The invention relates to a bioactive substance conjugate as well as a preparation method and application thereof, and particularly discloses a ligand drug conjugate as shown in a formula XV, a preparation method thereof and application of the ligand drug conjugate in prevention and / or treatment of diseases related to abnormal cell activity, including but not limited to prevention and / or treatment of tumor diseases. # imgabs0 #
Owner:MEDILINK THERAPEUTICS (SUZHOU) CO LTD

Central nervous system photogenetic modulation for treatment of pain

The present invention relates generally to compositions and methods for modulating cell activity using multi-characteristic opsin proteins (MCOs). In addition, the present invention provides methods of treating conditions associated with dorsal root ganglion (DRG), anterior clasps cortex (ACC), or spinal cord activity, including neuropathic pain. Particular embodiments include methods of modulating an inhibitory pathway to inhibit chronic neuropathic pain. The method may use a photosensitive optogenetic actuator with inhibitory neuron specificity. Embodiments also include an optogenetic pain regulator device that can regulate the frequency and intensity of optogenetic stimulation.
Owner:OPSIN BIOTHERAPEUTICS INC